IN O O O O
THROUGH O O O O
THE O O O O
NOSE... O O O O
COVID-19 O O O O
Nasal O O O O
Vaccine O O O O
Candidate O O O O
Effective O O O O
at O O O O
Preventing O O O O
Disease O O O O
Transmission O O O O
September O O O O
15, O O O O
2021 O O O O
- O O O O
Breathe O O O O
in, O O O O
breathe O O O O
out. O O O O
That's O O O O
how O O O O
easy O O O O
it O O O O
is O O O O
for O O O O
SARS-CoV-2, O O O O
the O O O O
virus O O O O
that O O O O
causes O O O O
COVID-19, O O O O
to O O O O
enter O O O O
your O O O O
nose. O O O O
And O O O O
though O O O O
remarkable O O O O
progress O O O O
has O O O O
been O O O O
made O O O O
in O O O O
developing O O O O
intramuscular O O O O
vaccines O O O O
against O O O O
SARS-CoV- O O O O
2, O O O O
such O O O O
as O O O O
the O O O O
readily O O O O
available O O O O
Pfizer, O O O O
Moderna O O O O
and O O O O
Johnson O O O O
& O O O O
Johnson O O O O
vaccines, O O O O
nothing O O O O
yet O O O O
- O O O O
like O O O O
a O O O O
nasal O O O O
vaccine O O O O
- O O O O
has O O O O
been O O O O
approved O O O O
to O O O O
provide O O O O
mucosal O O O O
immunity O O O O
in O O O O
the O O O O
nose, O O O O
the O O O O
first O O O O
barrier O O O O
against O O O O
the O O O O
virus O O O O
before O O O O
it O O O O
travels O O O O
down O O O O
to O O O O
the O O O O
lungs. O O O O
But O O O O
now, O O O O
we're O O O O
one O O O O
step O O O O
closer. O O O O
Navin O O O O
Varadarajan, O O O O
University O O O O
of O O O O
Houston O O O O
M.D. O O O O
Anderson O O O O
Professor O O O O
of O O O O
Chemical O O O O
and O O O O
Biomolecular O O O O
Engineering, O O O O
and O O O O
his O O O O
colleagues, O O O O
are O O O O
reporting O O O O
in O O O O
[iScience](https://www.sciencedirect.com/science/article/pii/S2589004221010051) O O O O
the O O O O
development O O O O
of O O O O
an O O O O
intranasal O O O O
subunit O O O O
vaccine O O O O
that O O O O
provides O O O O
durable O O O O
local O O O O
immunity O O O O
against O O O O
inhaled O O O O
pathogens. O O O O
"Mucosal Reason 4 O O
vaccination Reason 4 O O
can Reason 4 O O
stimulate Reason 4 O O
both Reason 4 O O
systemic Reason 4 O O
and Reason 4 O O
mucosal Reason 4 O O
immunity Reason 4 O O
and Reason 4 O O
has Reason 4 O O
the Reason 4 O O
advantage Reason 4 O O
of Reason 4 O O
being Reason 4 O O
a Reason 4 O O
non-invasive Reason 4 O O
procedure Reason 4 O O
suitable Reason 4 O O
for Reason 4 O O
immunization Reason 4 O O
of Reason 4 O O
large Reason 4 O O
populations," Reason 4 O O
said Reason 4 O O
Varadarajan. Reason 4 O O
"However, Reason 4 O O
mucosal Reason 4 O O
vaccination Reason 4 O O
has Reason 4 O O
been Reason 4 O O
hampered Reason 4 O O
by Reason 4 O O
the Reason 4 O O
lack Reason 4 O O
of Reason 4 O O
efficient Reason 4 O O
delivery Reason 4 O O
of Reason 4 O O
the Reason 4 O O
antigen Reason 4 O O
and Reason 4 O O
the Reason 4 O O
need Reason 4 O O
for Reason 4 O O
appropriate Reason 4 O O
adjuvants Reason 4 O O
that Reason 4 O O
can Reason 4 O O
stimulate Reason 4 O O
a Reason 4 O O
robust Reason 4 O O
immune Reason 4 O O
response Reason 4 O O
without Reason 4 O O
toxicity." Reason 4 O O
"Our O O O O
results O O O O
show O O O O
that O O O O
the O O O O
candidate O O O O
vaccine O O O O
formulation O O O O
is O O O O
safe, O O O O
produces O O O O
rapid O O O O
immune O O O O
responses O O O O
- O O O O
within O O O O
seven O O O O
days O O O O
- O O O O
and O O O O
elicits O O O O
comprehensive O O O O
immunity O O O O
against O O O O
SARS-CoV-2." O O O O
To Reason 2 O O
solve Reason 2 O O
those Reason 2 O O
problems, Reason 2 O O
Varadarajan Reason 2 O O
collaborated Reason 2 O O
with Reason 2 O O
Xinli Reason 2 O O
Liu, Reason 2 O O
associate Reason 2 O O
professor Reason 2 O O
of Reason 2 O O
pharmaceutics Reason 2 O O
at Reason 2 O O
the Reason 2 O O
UH Reason 2 O O
College Reason 2 O O
of Reason 2 O O
Pharmacy, Reason 2 O O
and Reason 2 O O
an Reason 2 O O
expert Reason 2 O O
in Reason 2 O O
nanoparticle Reason 2 O O
delivery. Reason 2 O O
Liu's Reason 2 O O
team Reason 2 O O
was Reason 2 O O
able Reason 2 O O
to Reason 2 O O
encapsulate Reason 2 O O
the Reason 2 O O
agonist Reason 2 O O
of Reason 2 O O
the Reason 2 O O
stimulator Reason 2 O O
of Reason 2 O O
interferon Reason 2 O O
genes Reason 2 O O
(STING) Reason 2 O O
within Reason 2 O O
liposomal Reason 2 O O
particles Reason 2 O O
to Reason 2 O O
yield Reason 2 O O
the Reason 2 O O
adjuvant Reason 2 O O
named Reason 2 O O
NanoSTING. Reason 2 O O
The Reason 2 O O
function Reason 2 O O
of Reason 2 O O
the Reason 2 O O
adjuvant Reason 2 O O
is Reason 2 O O
to Reason 2 O O
promote Reason 2 O O
the Reason 2 O O
body's Reason 2 O O
immune Reason 2 O O
response. Reason 2 O O
"NanoSTING Reason 2 O O
has Reason 2 O O
a Reason 2 O O
small Reason 2 O O
particle Reason 2 O O
size Reason 2 O O
around Reason 2 O O
100 Reason 2 O O
nanometers Reason 2 O O
which Reason 2 O O
exhibits Reason 2 O O
significantly Reason 2 O O
different Reason 2 O O
physical Reason 2 O O
and Reason 2 O O
chemical Reason 2 O O
properties Reason 2 O O
to Reason 2 O O
the Reason 2 O O
conventional Reason 2 O O
adjuvant," Reason 2 O O
said Reason 2 O O
Liu. Reason 2 O O
"We Reason 2 O O
used Reason 2 O O
NanoSTING Reason 2 O O
as Reason 2 O O
the Reason 2 O O
adjuvant Reason 2 O O
for Reason 2 O O
intranasal Reason 2 O O
vaccination Reason 2 O O
and Reason 2 O O
single-cell Reason 2 O O
RNA-sequencing Reason 2 O O
to Reason 2 O O
confirm Reason 2 O O
the Reason 2 O O
nasal-associated Reason 2 O O
lymphoid Reason 2 O O
tissue Reason 2 O O
as Reason 2 O O
an Reason 2 O O
inductive Reason 2 O O
site Reason 2 O O
upon Reason 2 O O
vaccination. Reason 2 O O
Our Reason 2 O O
results Reason 2 O O
show Reason 2 O O
that Reason 2 O O
the Reason 2 O O
candidate Reason 2 O O
vaccine Reason 2 O O
formulation Reason 2 O O
is Reason 2 O O
safe, Reason 2 O O
produces Reason 2 O O
rapid Reason 2 O O
immune Reason 2 O O
responses Reason 2 O O
- Reason 2 O O
within Reason 2 O O
seven Reason 2 O O
days Reason 2 O O
- Reason 2 O O
and Reason 2 O O
elicits Reason 2 O O
comprehensive Reason 2 O O
immunity Reason 2 O O
against Reason 2 O O
SARS-CoV-2," Reason 2 O O
said Reason 2 O O
Varadarajan. Reason 2 O O
"Equitable O O O O
distribution O O O O
requires O O O O
vaccines O O O O
that O O O O
are O O O O
stable O O O O
and O O O O
that O O O O
can O O O O
be O O O O
shipped O O O O
easily." O O O O
A Reason 4 O O
fundamental Reason 4 O O
limitation Reason 4 O O
of Reason 4 O O
intramuscular Reason 4 O O
vaccines Reason 4 O O
is Reason 4 O O
that Reason 4 O O
they Reason 4 O O
are Reason 4 O O
not Reason 4 O O
designed Reason 4 O O
to Reason 4 O O
elicit Reason 4 O O
mucosal Reason 4 O O
immunity. Reason 4 O O
As Reason 4 O O
prior Reason 4 O O
work Reason 4 O O
with Reason 4 O O
other Reason 4 O O
respiratory Reason 4 O O
pathogens Reason 4 O O
like Reason 4 O O
influenza Reason 4 O O
has Reason 4 O O
shown, Reason 4 O O
sterilizing Reason 4 O O
immunity Reason 4 O O
to Reason 4 O O
virus Reason 4 O O
re-infection Reason 4 O O
requires Reason 4 O O
adaptive Reason 4 O O
immune Reason 4 O O
responses Reason 4 O O
in Reason 4 O O
the Reason 4 O O
respiratory Reason 4 O O
tract Reason 4 O O
and Reason 4 O O
the Reason 4 O O
lung. Reason 4 O O
The O O O O
nasal O O O O
vaccine O O O O
will O O O O
also O O O O
serve O O O O
to O O O O
equitably O O O O
distribute O O O O
vaccines O O O O
worldwide, O O O O
according Reason 4 O O
to Reason 4 O O
the Reason 4 O O
researchers. Reason 4 O O
It Reason 4 O O
is Reason 4 O O
estimated Reason 4 O O
that Reason 4 O O
first Reason 4 O O
world Reason 4 O O
countries Reason 4 O O
have Reason 4 O O
already Reason 4 O O
secured Reason 4 O O
and Reason 4 O O
vaccinated Reason 4 O O
multiple Reason 4 O O
intramuscular Reason 4 O O
doses Reason 4 O O
for Reason 4 O O
each Reason 4 O O
citizen Reason 4 O O
while Reason 4 O O
billions Reason 4 O O
of Reason 4 O O
people Reason 4 O O
in Reason 4 O O
countries Reason 4 O O
like Reason 4 O O
India, Reason 4 O O
South Reason 4 O O
Africa, Reason 4 O O
and Reason 4 O O
Brazil Reason 4 O O
with Reason 4 O O
large Reason 4 O O
outbreaks Reason 4 O O
are Reason 4 O O
currently Reason 4 O O
not Reason 4 O O
immunized. Reason 4 O O
These Reason 4 O O
outbreaks Reason 4 O O
and Reason 4 O O
viral Reason 4 O O
spread Reason 4 O O
are Reason 4 O O
known Reason 4 O O
to Reason 4 O O
facilitate Reason 4 O O
viral Reason 4 O O
evolution Reason 4 O O
leading Reason 4 O O
to Reason 4 O O
decreased Reason 4 O O
efficacy Reason 4 O O
of Reason 4 O O
all Reason 4 O O
vaccines. Reason 4 O O
"Equitable O O O O
distribution O O O O
requires O O O O
vaccines O O O O
that O O O O
are O O O O
stable O O O O
and O O O O
that O O O O
can O O O O
be O O O O
shipped O O O O
easily. O O O O
As Reason 4 O O
we Reason 4 O O
have Reason 4 O O
shown, Reason 4 O O
each Reason 4 O O
of Reason 4 O O
our Reason 4 O O
components, Reason 4 O O
the Reason 4 O O
protein Reason 4 O O
(lyophilized) Reason 4 O O
and Reason 4 O O
the Reason 4 O O
adjuvant Reason 4 O O
(NanoSTING) Reason 4 O O
are Reason 4 O O
stable Reason 4 O O
for Reason 4 O O
over Reason 4 O O
11 Reason 4 O O
months Reason 4 O O
and Reason 4 O O
can Reason 4 O O
be Reason 4 O O
stored Reason 4 O O
and Reason 4 O O
shipped Reason 4 O O
without Reason 4 O O
the Reason 4 O O
need Reason 4 O O
for Reason 4 O O
freezing," Reason 4 O O
said Reason 4 O O
Varadarajan. Reason 4 O O
Varadarajan O O O O
is O O O O
co-founder O O O O
of O O O O
AuraVax O O O O
Therapeutics O O O O
Inc., O O O O
a O O O O
pioneering O O O O
biotech O O O O
company O O O O
developing O O O O
novel O O O O
intranasal O O O O
vaccines O O O O
and O O O O
therapies O O O O
to O O O O
help O O O O
patients O O O O
defeat O O O O
debilitating O O O O
diseases, O O O O
including O O O O
COVID-19. O O O O
The O O O O
company O O O O
has O O O O
an O O O O
exclusive O O O O
license O O O O
agreement O O O O
with O O O O
UH O O O O
with O O O O
respect O O O O
to O O O O
the O O O O
intellectual O O O O
property O O O O
covering O O O O
intranasal O O O O
vaccines O O O O
and O O O O
STING O O O O
agonist O O O O
technologies. O O O O
They O O O O
have O O O O
initiated O O O O
the O O O O
manufacturing O O O O
process O O O O
and O O O O
plan O O O O
to O O O O
engage O O O O
the O O O O
FDA O O O O
later O O O O
this O O O O
year. O O O O
Along O O O O
with O O O O
Liu, O O O O
Varadarajan's O O O O
team O O O O
includes O O O O
postdoctoral O O O O
researchers O O O O
Xingyue O O O O
An, O O O O
Melisa O O O O
Sujit O O O O
Biswas; O O O O
doctoral O O O O
student O O O O
Samiur O O O O
Rahman O O O O
Sefat, O O O O
all O O O O
from O O O O
the O O O O
University O O O O
of O O O O
Houston; O O O O
and O O O O
Shailbala O O O O
Sing, O O O O
postdoctoral O O O O
researcher O O O O
at O O O O
University O O O O
of O O O O
Texas O O O O
M. O O O O
D. O O O O
Anderson O O O O
Cancer O O O O
Center; O O O O
Melissa O O O O
Pourpak, O O O O
BD; O O O O
and O O O O
Cassian O O O O
Yee, O O O O
M.D., O O O O
University O O O O
of O O O O
Texas O O O O
M. O O O O
D. O O O O
Anderson O O O O
Cancer O O O O
Center O O O O
